勤浩医药完成超3亿元Crossover轮融资，持续创新再提速

2026年1月13日，中国苏州——致力于利用组合技术平台开发全球新一代抗肿瘤小分子药物的研发企业，勤浩医药今日宣布，已完成超3亿元人民币Crossover轮融资。本轮融资由松禾资本领投，林拙投资、元生创投、广州产投、VIVATEC、薄荷基金、国聚投资等多家机构共同参与。

作为自主创新驱动的Biotech公司，勤浩医药始终聚焦于全球领先的靶向抗肿瘤小分子药物开发。公司构建了“AI/Biology-Driven Smart Design”的药物开发理念，深度融合计算化学、人工智能与内部实验平台，形成“数据驱动、快速迭代”的高效研发体系，全面赋能从药物发现至临床开发的全流程。 

公司已建立涵盖Ras信号通路与合成致死领域的差异化管线，并推动多个全球领先的项目进入临床阶段，展现了持续创新的能力，也望为难治性肿瘤的精准治疗和联合治疗提供具备国际竞争力的解决方案。

凭借平台创新实力与管线潜力，勤浩医药连续获得“姑苏重大创新团队”、“江苏省重大专项”，并参与“创新药物研发国家科技重大专项”，技术路径与创新价值获多方认可。

此次融资的完成，将进一步加速公司研发进程与战略布局。未来，勤浩医药将依托AI赋能的高效创新体系，聚焦未被满足的临床需求，携手产学研各界，继续推动具有全球竞争力的创新药开发，为患者带来突破性治疗方案。

Abstract:SUZHOU, China, January 13, 2026 — GenHouse Bio Co., Ltd., a clinical-stage biotechnology company dedicated to developing next-generation small-molecule oncology therapies via integrated technology platforms, today announced the successful completion of a crossover financing round exceeding RMB 300 million. The round was led by GreenPine Capital Partners, with participation from a syndicate of prominent investors including LinZhuo Investment, YuanBio Venture Capital, Guangzhou Industrial Investment, VIVATEC, BoHe Angel Fund, Guoju Entrepreneurship Investment.

AI-Driven R&D and High-Efficiency Innovation

As an innovation-driven biotech company, GenHouse Bio remains steadfast in its focus on developing world-leading targeted small-molecule anti-tumor drugs. The company has built a drug-discovery philosophy of “AI/Biology-Driven Smart Design,” deeply integrating computational chemistry, artificial intelligence, and in-house experimental platforms to create an efficient, data-driven, rapidly iterative R&D system that empowers the entire process from drug discovery to clinical development.

Differentiated Pipeline and Clinical Progress

GenHouse Bio has established differentiated pipelines covering the Ras signaling pathway and synthetic-lethal fields, advancing multiple world-leading programs into clinical stages. This demonstrates its sustained innovation capability and is expected to provide internationally competitive solutions for precision and combination therapies of refractory tumors. The company’s platform capabilities and pipeline potential have earned prestigious recognitions, including the "Gusu Major Innovation Team" and "Jiangsu Provincial Major Project" awards. Furthermore, GenHouse Bio has participated in the "National Key Science and Technology Program for Innovative Drug Development," reflecting broad institutional validation of its technical roadmap and innovative value.

Strategic Outlook

The completion of this financing round will further accelerate the company’s R&D progress and strategic layout. Looking ahead, GenHouse Bio will continue to leverage its AI-empowered highly efficient innovative system to address unmet clinical needs. By collaborating with partners across industry, academia, and research partners, the company remains committed to advancing globally competitive innovative drugs and delivering breakthrough treatment solutions to patients worldwide.

关于勤浩医药

勤浩医药（苏州）股份有限公司作为一家人工智能驱动的Biotech，聚焦于全球领先的靶向抗肿瘤小分子药物开发，公司紧密围绕流程化、模块化的创新药研发体系，全方位的依托AI赋能，基于首创提出的 “AI/Biology-Driven Smart Design” 的药物开发理念，打造了具有自主持续创新能力的组合技术平台：结构生物学平台、新药发现与设计平台、成药性评价平台、转化医学平台，深耕Ras-MAPK信号通路（1.0管线）和合成致死领域（2.0管线），形成了以靶向抗肿瘤品种为核心的产品管线。